AAAAAA

   
Results: 1-3 |
Results: 3
Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: A double-blind placebo-controlled trial - The cardiovascular thrombolytic to open occluded lines (COOL) efficacy trial
Authors: Ponec, D Irwin, D Haire, WD Hill, PA Li, X McCluskey, ER
Citation: D. Ponec et al., Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: A double-blind placebo-controlled trial - The cardiovascular thrombolytic to open occluded lines (COOL) efficacy trial, J VAS INT R, 12(8), 2001, pp. 951-955
Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease
Authors: Henry, TD Rocha-Singh, K Isner, JM Kereiakes, DJ Giordano, FJ Simons, M Losordo, DW Hendel, RC Bonow, RO Eppler, SM Zioncheck, TF Holmgren, EB McCluskey, ER
Citation: Td. Henry et al., Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease, AM HEART J, 142(5), 2001, pp. 872-880
Vascular endothelial growth factor (VEGF) protein therapy for ischemic coronary disease
Authors: McCluskey, ER
Citation: Er. Mccluskey, Vascular endothelial growth factor (VEGF) protein therapy for ischemic coronary disease, HANDBOOK OF MYOCARDIAL REVASCULARIZATION AND ANGIOGENESIS, 2000, pp. 119-124
Risultati: 1-3 |